Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Jan 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-01-01

Reporting Person: O'Brien Stephanie Monaghan (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-01	Stock Option (Right to Buy)	$30.62	A	27600	Acquired	2029-12-31	Common Stock (27600)	Direct

Footnotes

F1: This option was granted 01/01/2020. The option vests quarterly over 1 year on the last day of each quarter from grant date.